FDA sets May 2027 review date for uniQure's Huntington's gene therapyThe FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.Nov 2, 2026·2 sourcesNeurodegenerative diseaseFDA drug approvalClinical trialsGene therapyGenetic diseasesAccelerated approval pathwaysDrug Policy, Pricing & Approval00
